According to the partners’ memo of understanding, Nanolek is planning to use its production site in the Kirov region some 950km
The MoU is paving the way for Sanofi Pasteur to transfer its vaccine technology to its Russian partner.
Nanolek, a Russian biotech company, has agreed with France’s Sanofi Pasteur, a global leader in vaccine development, on the setup of Russian-based production of a vaccine to prevent dangerous children’s diseases, Rusnano reported. The Russian nanotech giant established Nanolek as its portfolio company back in 2011.
According to the partners’ memo of understanding, Nanolek is planning to use its production site in the Kirov region some 950km
The MoU is paving the way for Sanofi Pasteur to transfer its vaccine technology to its Russian partner.